Halozyme Therapeutics Inc (HALO)

Debt-to-capital ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 1,499,250 1,497,620 1,496,000 1,494,380 1,492,770 1,491,160 — — 787,255 — — — 0 — — — 383,045 — — —
Total stockholders’ equity US$ in thousands 83,808 249,181 151,033 65,850 169,798 96,991 293,171 260,256 196,953 281,674 119,746 67,595 151,047 98,988 105,577 58,042 91,765 245,353 260,052 260,047
Debt-to-capital ratio 0.95 0.86 0.91 0.96 0.90 0.94 0.00 0.00 0.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.81 0.00 0.00 0.00

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,499,250K ÷ ($1,499,250K + $83,808K)
= 0.95

The debt-to-capital ratio measures the proportion of a company's capital structure that is funded by debt. A higher ratio indicates a higher level of debt relative to total capital, which may pose higher financial risk and leverage for the company.

Analyzing the trend of Halozyme Therapeutics Inc.'s debt-to-capital ratio over the past quarters, we observe fluctuations in the ratio. In Q4 2023, the ratio was 0.95, which is relatively high compared to previous quarters. This suggests that a significant portion of the company's capital is financed through debt.

The ratio decreased in Q3 2023 to 0.86, indicating a lower reliance on debt funding. However, in Q2 and Q1 2023, the ratio increased to 0.91 and 0.96, respectively, suggesting a trend towards higher debt levels in the capital structure.

Comparing to the same quarters in the previous year, we see a similar pattern of fluctuation with the ratio ranging from 0.77 to 0.94. This indicates that the company's debt levels have been varying over time, potentially due to changes in financing activities or business operations.

Overall, the trend of Halozyme Therapeutics Inc.'s debt-to-capital ratio shows variability in debt usage, which may have implications for the company's financial risk, cost of capital, and future borrowing capacity. Further analysis of the company's overall financial position and debt management strategies would provide deeper insights into the implications of these ratio fluctuations.